Valneva SE (VALN) stock
VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.66−0.10 (-1.74%)
Close on Nov 13, 2026Market cap $491.12MP/E –Yield –
Valneva EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -0.68 EUR. The highest annual figure on record is -0.02 EUR in fiscal 2019.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -0.68 EUR | – |
| FY2024 | Dec 31, 2024 | -0.08 EUR | – |
| FY2023 | Dec 31, 2023 | -0.73 EUR | – |
| FY2022 | Dec 31, 2022 | -1.24 EUR | – |
| FY2021 | Dec 31, 2021 | -0.75 EUR | – |
| FY2020 | Dec 31, 2020 | -0.71 EUR | – |
| FY2019 | Dec 31, 2019 | -0.02 EUR | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -0.18 EUR | – |
| Q1 FY2025 | Mar 31, 2025 | -0.06 EUR | – |
| Q1 FY2024 | Mar 31, 2024 | 0.41 EUR | – |
| Q1 FY2023 | Mar 31, 2023 | -0.13 EUR | – |
| Q1 FY2022 | Mar 31, 2022 | -0.24 EUR | – |
| Q1 FY2021 | Mar 31, 2021 | -0.30 EUR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?